Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Public ClinicalTrials.gov record NCT04262466. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Study identification
- NCT ID
- NCT04262466
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 410 participants
Conditions and interventions
Conditions
Interventions
- Brenetafusp Drug
- Brenetafusp and pembrolizumab Drug
- Brenetafusp and chemotherapy Drug
- Brenetafusp and monoclonal antibodies and chemotherapy Drug
- Brenetafusp and tebentafusp Drug
- Brenetafusp and bevacizumab Drug
- Brenetafusp and kinase inhibitors Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 24, 2020
- Primary completion
- Sep 30, 2026
- Completion
- Nov 30, 2027
- Last update posted
- Mar 5, 2026
2020 – 2027
United States locations
- U.S. sites
- 22
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California - San Diego | La Jolla | California | 92093 | — |
| Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| University of California Davis Comprehensive Center | Sacramento | California | 95817 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20057 | — |
| Houston Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering | New York | New York | 10065 | — |
| University of Oklahoma Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Prisma Health | Greenville | South Carolina | 92697 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah - Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Washington - Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| University of Wisconsin | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04262466, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04262466 live on ClinicalTrials.gov.